125 patents
Page 3 of 7
Utility
Processes for Generating Til Products Enriched for Tumor Antigen-specific T-cells
27 Oct 22
The present invention provides improved and/or shortened processes and methods for reprogramming TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy.
Cecile CHARTIER-COURTAUD, Krit RITTHIPICHAI
Filed: 4 May 22
Utility
Expansion of TILs from Cryopreserved Tumor Samples
13 Oct 22
Methods of expanding tumor infiltrating lymphocytes (TILs) from cryopreserved tumor tissue and methods of using the expanded TILs in the treatment of human diseases, including cancers, are disclosed.
Anand Veerapathran, Kenneth Onimus
Filed: 20 Sep 19
Utility
Methods and Compositions for T-cell Coculture Potency Assays and Use with Cell Therapy Products
6 Oct 22
The present invention provides novel processes, compositions, and methods for analyzing or assaying the potency and/or functionality of tumor infiltrating lymphocyte (TIL) products for use in therapy, including human cancer therapy, and analyzing or assaying the potency and/or functionality of other polyclonal products, such as marrow infiltrating lymphocyte (MIL) and peripheral blood lymphocyte (PBL) products.
Michelle R. Simpson-Abelson, Matthew J. Frigault, Wayne P. Rothbaum, Michael Weiser
Filed: 25 Mar 22
Utility
Engineered Artificial Antigen Presenting Cells for Tumor Infiltrating Lymphocyte Expansion
6 Oct 22
In some embodiments, compositions and methods relating to isolated artificial antigen presenting cells (aAPCs) are disclosed, including aAPCs comprising a myeloid cell transduced with one or more viral vectors, such as a MOLM-14 or a EM-3 myeloid cell, wherein the myeloid cell endogenously expresses HLA-A/B/C, ICOS-L, and CD58, and wherein the one or more viral vectors comprise a nucleic acid encoding CD86 and a nucleic acid encoding 4-1BBL and/or OX40L and transduce the myeloid cell to express CD86 and 4-1BBL and/or OX40L proteins.
Anand Veerapathran, Aishwarya Gokuldass, Brian Rabinovich, Michael T. Lotze
Filed: 13 Apr 21
Utility
Engineered Artificial Antigen Presenting Cells for Tumor Infiltrating Lymphocyte Expansion
6 Oct 22
In some embodiments, compositions and methods re¬lating to isolated artificial antigen presenting cells (aAPCs) are dis¬closed, including aAPCs comprising a myeloid cell transduced with one or more viral vectors, such as a MOLM-14 or a EM-3 myeloid cell, wherein the myeloid cell endogenously expresses HLA-A/B/C, ICOS-L, and CD58, and wherein the one or more viral vectors com¬prise a nucleic acid encoding CD86 and a nucleic acid encoding 4-1BBL and/or OX40L and transduce the myeloid cell to express CD86 and 4-1BBL and/or OX40L proteins.
Anand Veerapathran, Aishwarya Gokuldass, Brian Rabinovich, Michael T. Lotze
Filed: 13 Apr 21
Utility
Methods and Compositions for Selecting Tumor Infiltrating Lymphocytes and Uses of the Same In Immunotherapy
11 Aug 22
The present invention provides improved methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for selecting TILs responsive to a mutant polypeptide expressed by cancer cells and not expressed in normal tissue.
Seth Wardell, Maritza Lienlaf Moreno, Cecile Chartier-Courtaud, Lavakumar Karyampudi
Filed: 12 May 20
Utility
Processes for Generating Til Products Enriched for Tumor Antigen-specific T-cells
30 Jun 22
The present invention provides improved and/or shortened processes and methods for reprogramming TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy.
Cecile Chartier-Courtaud, Krit Ritthipichai
Filed: 8 Jan 19
Utility
Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof
23 Jun 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Cecile Chartier-Courtaud, Maria Fardis
Filed: 12 Dec 19
Utility
Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof
5 May 22
Methods of expanding peripheral blood lymphocytes (PBLs) from blood of patients with hematological malignancies, including lymphomas and leukemias, genetic modifications of expanded PBLs to incorporate chimeric antigen receptors, genetically modified T cell receptors, and other genetic modifications, and uses of such expanded and/or modified PBLs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.
Lavakumar Karyampudi
Filed: 28 Feb 20
Utility
Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes
5 May 22
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 11 Dec 21
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
21 Apr 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth WARDELL
Filed: 9 May 19
Utility
Treatment of NSCLC Patients Refractory for ANTI-PD-1 Antibody
21 Apr 22
The present invention provides improved and/or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of non-small cell lung carcinoma (NSCLC), wherein the NSCLC is refractory to treatment with an anti-PD-1 antibody.
Maria Fardis, Arvind Natarajan
Filed: 3 Sep 19
Utility
Systems and Methods for Coordinating Manufacturing of Cells for Patient-specific Immunotherapy
21 Apr 22
A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient.
Anne Brooks, Steve Macrides, Kristin Lanzi
Filed: 6 Jan 22
Utility
System and Methods for Monitoring Adoptive Cell Therapy Clonality and Persistence
14 Apr 22
Methods and systems for identifying clinically effective population of tumor infiltrating lymphocytes are disclosed.
Cecile Chartier-Courtaud, Viktoria Gontcharova
Filed: 10 Jan 20
Utility
Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes
31 Mar 22
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 11 Dec 21
Utility
Treatment of NSCLC Patients Refractory for ANTI-PD-1 Antibody
24 Mar 22
The present invention provides improved and/or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of non-small cell lung carcinoma (NSCLC), wherein the NSCLC is refractory to treatment with an anti-PD-1 antibody.
Maria Fardis, Arvind Natarajan
Filed: 14 May 20
Utility
Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes
24 Mar 22
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 9 Dec 21
Utility
Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes
24 Mar 22
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 9 Dec 21
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Used of the Same In Immunotherapy
24 Mar 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, Maritza Lienlaf Moreno
Filed: 4 Nov 19
Utility
Methods of Using Tumor Infiltrating Lymphocytes In Double-refractory Melanoma
10 Mar 22
Methods of treating melanomas refractory to other therapies using tumor infiltrating lymphocytes are disclosed.
Maria Fardis
Filed: 5 Dec 18